Intravitreal bevacizumab monotherapy in myopic choroidal neovascularisation: 5-year outcomes for the PAN-American Collaborative Retina Study Group
PURPOSE: To report the long-term anatomical and visual outcomes of intravitreal bevacizumab (IVB) monotherapy in naive choroidal neovascularisation (CNV) caused by myopia. METHODS: Retrospective analysis of naive CNV secondary to myopia that underwent antivascular endothelial growth factor monothera...
Guardado en:
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | inglés |
| Publicado: |
2017
|
| Materias: | |
| Acceso en línea: | Ver en el sistema de origen Enlace permanente (DOI o Handle) |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1881508926684397568 |
|---|---|
| author | Jay Chhablani Remya Paulose Andrés F. Lasave Lihteh Wu Cristián Carpentier Maurício Maia Silvio Lujan Sergio Rojas Martín Serrano María H. Berrocal J. Fernando Arévalo |
| author_browse | Andrés F. Lasave Cristián Carpentier J. Fernando Arévalo Jay Chhablani Lihteh Wu Martín Serrano María H. Berrocal Maurício Maia Remya Paulose Sergio Rojas Silvio Lujan |
| author_facet | Jay Chhablani Remya Paulose Andrés F. Lasave Lihteh Wu Cristián Carpentier Maurício Maia Silvio Lujan Sergio Rojas Martín Serrano María H. Berrocal J. Fernando Arévalo |
| author_sort | Jay Chhablani |
| collection | Producción científica |
| description | PURPOSE: To report the long-term anatomical and visual outcomes of intravitreal bevacizumab (IVB) monotherapy in naive choroidal neovascularisation (CNV) caused by myopia. METHODS: Retrospective analysis of naive CNV secondary to myopia that underwent antivascular endothelial growth factor monotherapy was performed. Collected data included demographic details, clinical examination details including visual acuity at presentation and follow-up with imaging and treatment details. Main outcome measures were resolution of CNV activity at the last visit. Secondary outcomes included change in visual acuity, number of injections and adverse events. RESULTS: Thirty-three eyes of 31 subjects with a mean age of 51.48±16.4 years were included. The mean follow-up was 66.47 months. 27 eyes had type 2 CNV and the rest seven eyes had type 1 CNV. The mean number of IVB injections per eye was 4.9. Mean visual acuity at baseline reduced from 0.65±0.33 logMAR units (Snellen equivalent=20/89) to 0.73±0.50 logMAR units (20/107) at final follow-up (p=0.003). The mean central macular thickness decreased from 309.31±86 µm at baseline to 267.5±70.89 µm at the last visit (p=0.03). However, visual acuity was maintained (±1 line of baseline) in 13 eyes (39.4%), ≥2 line improvement in nine (27.3%) eyes and more than two lines worsening in 11 eyes (33.3%). Foveal atrophy was observed at baseline and last visit in 6 (12.5%) and 14 (29.1%), respectively (p=0.007). No systemic adverse events were observed. CONCLUSION: IVB monotherapy is safe and effective for long-term treatment of CNV secondary to myopia in real life. |
| format | Article |
| id | oai:cris.upeu.edu.pe:20.500.15037/929 |
| institution | UPeU |
| language | English |
| publishDate | 2017 |
| publishDateRange | 2017 |
| publishDateSort | 2017 |
| record_format | dspace |
| spelling | oai:cris.upeu.edu.pe:20.500.15037/9292026-10-30T16:14:59ZIntravitreal bevacizumab monotherapy in myopic choroidal neovascularisation: 5-year outcomes for the PAN-American Collaborative Retina Study GroupJay ChhablaniRemya PauloseAndrés F. LasaveLihteh WuCristián CarpentierMaurício MaiaSilvio LujanSergio RojasMartín SerranoMaría H. BerrocalJ. Fernando ArévaloMedicineVisual acuityOphthalmologyMacular degenerationBevacizumabChoroidal neovascularizationGeographic atrophySurgeryChemotherapyMedicineVisual acuityOphthalmologyMacular degenerationBevacizumabChoroidal neovascularizationGeographic atrophySurgeryChemotherapyBevacizumab administration & dosageBevacizumab administration & dosageBevacizumab administration & dosageAdultAdultAdultAgedAgedAgedAged, 80 and overAged, 80 and overAged, 80 and overFemaleFemaleFemaleHumansHumansHumansMaleMaleMaleMiddle AgedMiddle AgedMiddle AgedMyopia complicationsMyopia complicationsMyopia complicationsRetrospective StudiesRetrospective StudiesRetrospective StudiesVisual Acuity physiologyVisual Acuity physiologyVisual Acuity physiologyChoroidal Neovascularization drug therapyChoroidal Neovascularization drug therapyChoroidal Neovascularization drug therapyChoroidal Neovascularization etiologyChoroidal Neovascularization etiologyChoroidal Neovascularization etiologyChoroidal Neovascularization physiopathologyChoroidal Neovascularization physiopathologyChoroidal Neovascularization physiopathologyAngiogenesis Inhibitors administration & dosageAngiogenesis Inhibitors administration & dosageAngiogenesis Inhibitors administration & dosageHealth Sciences Medicine Ophthalmology Retinal Diseases and TreatmentsHealth Sciences Medicine Ophthalmology Ocular Diseases and Behçet’s SyndromeHealth Sciences Medicine Radiology, Nuclear Medicine and Imaging Corneal Surgery and TreatmentsPURPOSE: To report the long-term anatomical and visual outcomes of intravitreal bevacizumab (IVB) monotherapy in naive choroidal neovascularisation (CNV) caused by myopia. METHODS: Retrospective analysis of naive CNV secondary to myopia that underwent antivascular endothelial growth factor monotherapy was performed. Collected data included demographic details, clinical examination details including visual acuity at presentation and follow-up with imaging and treatment details. Main outcome measures were resolution of CNV activity at the last visit. Secondary outcomes included change in visual acuity, number of injections and adverse events. RESULTS: Thirty-three eyes of 31 subjects with a mean age of 51.48±16.4 years were included. The mean follow-up was 66.47 months. 27 eyes had type 2 CNV and the rest seven eyes had type 1 CNV. The mean number of IVB injections per eye was 4.9. Mean visual acuity at baseline reduced from 0.65±0.33 logMAR units (Snellen equivalent=20/89) to 0.73±0.50 logMAR units (20/107) at final follow-up (p=0.003). The mean central macular thickness decreased from 309.31±86 µm at baseline to 267.5±70.89 µm at the last visit (p=0.03). However, visual acuity was maintained (±1 line of baseline) in 13 eyes (39.4%), ≥2 line improvement in nine (27.3%) eyes and more than two lines worsening in 11 eyes (33.3%). Foveal atrophy was observed at baseline and last visit in 6 (12.5%) and 14 (29.1%), respectively (p=0.007). No systemic adverse events were observed. CONCLUSION: IVB monotherapy is safe and effective for long-term treatment of CNV secondary to myopia in real life.Articlehttps://pubmed.ncbi.nlm.nih.gov/2881441710.1136/bjophthalmol-2017-310411https://hdl.handle.net/20.500.15037/929W2746119426enBritish Journal of Ophthalmology0007-11611468-20792017-08-162026-06-13T09:40:45Z2026-06-13T09:40:45Z |
| spellingShingle | Medicine Visual acuity Ophthalmology Macular degeneration Bevacizumab Choroidal neovascularization Geographic atrophy Surgery Chemotherapy Medicine Visual acuity Ophthalmology Macular degeneration Bevacizumab Choroidal neovascularization Geographic atrophy Surgery Chemotherapy Bevacizumab administration & dosage Bevacizumab administration & dosage Bevacizumab administration & dosage Adult Adult Adult Aged Aged Aged Aged, 80 and over Aged, 80 and over Aged, 80 and over Female Female Female Humans Humans Humans Male Male Male Middle Aged Middle Aged Middle Aged Myopia complications Myopia complications Myopia complications Retrospective Studies Retrospective Studies Retrospective Studies Visual Acuity physiology Visual Acuity physiology Visual Acuity physiology Choroidal Neovascularization drug therapy Choroidal Neovascularization drug therapy Choroidal Neovascularization drug therapy Choroidal Neovascularization etiology Choroidal Neovascularization etiology Choroidal Neovascularization etiology Choroidal Neovascularization physiopathology Choroidal Neovascularization physiopathology Choroidal Neovascularization physiopathology Angiogenesis Inhibitors administration & dosage Angiogenesis Inhibitors administration & dosage Angiogenesis Inhibitors administration & dosage Health Sciences Medicine Ophthalmology Retinal Diseases and Treatments Health Sciences Medicine Ophthalmology Ocular Diseases and Behçet’s Syndrome Health Sciences Medicine Radiology, Nuclear Medicine and Imaging Corneal Surgery and Treatments Jay Chhablani Remya Paulose Andrés F. Lasave Lihteh Wu Cristián Carpentier Maurício Maia Silvio Lujan Sergio Rojas Martín Serrano María H. Berrocal J. Fernando Arévalo Intravitreal bevacizumab monotherapy in myopic choroidal neovascularisation: 5-year outcomes for the PAN-American Collaborative Retina Study Group |
| title | Intravitreal bevacizumab monotherapy in myopic choroidal neovascularisation: 5-year outcomes for the PAN-American Collaborative Retina Study Group |
| title_full | Intravitreal bevacizumab monotherapy in myopic choroidal neovascularisation: 5-year outcomes for the PAN-American Collaborative Retina Study Group |
| title_fullStr | Intravitreal bevacizumab monotherapy in myopic choroidal neovascularisation: 5-year outcomes for the PAN-American Collaborative Retina Study Group |
| title_full_unstemmed | Intravitreal bevacizumab monotherapy in myopic choroidal neovascularisation: 5-year outcomes for the PAN-American Collaborative Retina Study Group |
| title_short | Intravitreal bevacizumab monotherapy in myopic choroidal neovascularisation: 5-year outcomes for the PAN-American Collaborative Retina Study Group |
| title_sort | intravitreal bevacizumab monotherapy in myopic choroidal neovascularisation 5 year outcomes for the pan american collaborative retina study group |
| topic | Medicine Visual acuity Ophthalmology Macular degeneration Bevacizumab Choroidal neovascularization Geographic atrophy Surgery Chemotherapy Medicine Visual acuity Ophthalmology Macular degeneration Bevacizumab Choroidal neovascularization Geographic atrophy Surgery Chemotherapy Bevacizumab administration & dosage Bevacizumab administration & dosage Bevacizumab administration & dosage Adult Adult Adult Aged Aged Aged Aged, 80 and over Aged, 80 and over Aged, 80 and over Female Female Female Humans Humans Humans Male Male Male Middle Aged Middle Aged Middle Aged Myopia complications Myopia complications Myopia complications Retrospective Studies Retrospective Studies Retrospective Studies Visual Acuity physiology Visual Acuity physiology Visual Acuity physiology Choroidal Neovascularization drug therapy Choroidal Neovascularization drug therapy Choroidal Neovascularization drug therapy Choroidal Neovascularization etiology Choroidal Neovascularization etiology Choroidal Neovascularization etiology Choroidal Neovascularization physiopathology Choroidal Neovascularization physiopathology Choroidal Neovascularization physiopathology Angiogenesis Inhibitors administration & dosage Angiogenesis Inhibitors administration & dosage Angiogenesis Inhibitors administration & dosage Health Sciences Medicine Ophthalmology Retinal Diseases and Treatments Health Sciences Medicine Ophthalmology Ocular Diseases and Behçet’s Syndrome Health Sciences Medicine Radiology, Nuclear Medicine and Imaging Corneal Surgery and Treatments |
| topic_facet | Medicine Visual acuity Ophthalmology Macular degeneration Bevacizumab Choroidal neovascularization Geographic atrophy Surgery Chemotherapy Medicine Visual acuity Ophthalmology Macular degeneration Bevacizumab Choroidal neovascularization Geographic atrophy Surgery Chemotherapy Bevacizumab administration & dosage Bevacizumab administration & dosage Bevacizumab administration & dosage Adult Adult Adult Aged Aged Aged Aged, 80 and over Aged, 80 and over Aged, 80 and over Female Female Female Humans Humans Humans Male Male Male Middle Aged Middle Aged Middle Aged Myopia complications Myopia complications Myopia complications Retrospective Studies Retrospective Studies Retrospective Studies Visual Acuity physiology Visual Acuity physiology Visual Acuity physiology Choroidal Neovascularization drug therapy Choroidal Neovascularization drug therapy Choroidal Neovascularization drug therapy Choroidal Neovascularization etiology Choroidal Neovascularization etiology Choroidal Neovascularization etiology Choroidal Neovascularization physiopathology Choroidal Neovascularization physiopathology Choroidal Neovascularization physiopathology Angiogenesis Inhibitors administration & dosage Angiogenesis Inhibitors administration & dosage Angiogenesis Inhibitors administration & dosage Health Sciences Medicine Ophthalmology Retinal Diseases and Treatments Health Sciences Medicine Ophthalmology Ocular Diseases and Behçet’s Syndrome Health Sciences Medicine Radiology, Nuclear Medicine and Imaging Corneal Surgery and Treatments |
| url | https://pubmed.ncbi.nlm.nih.gov/28814417 https://hdl.handle.net/20.500.15037/929 |
| work_keys_str_mv | AT jaychhablani intravitrealbevacizumabmonotherapyinmyopicchoroidalneovascularisation5yearoutcomesforthepanamericancollaborativeretinastudygroup AT remyapaulose intravitrealbevacizumabmonotherapyinmyopicchoroidalneovascularisation5yearoutcomesforthepanamericancollaborativeretinastudygroup AT andresflasave intravitrealbevacizumabmonotherapyinmyopicchoroidalneovascularisation5yearoutcomesforthepanamericancollaborativeretinastudygroup AT lihtehwu intravitrealbevacizumabmonotherapyinmyopicchoroidalneovascularisation5yearoutcomesforthepanamericancollaborativeretinastudygroup AT cristiancarpentier intravitrealbevacizumabmonotherapyinmyopicchoroidalneovascularisation5yearoutcomesforthepanamericancollaborativeretinastudygroup AT mauriciomaia intravitrealbevacizumabmonotherapyinmyopicchoroidalneovascularisation5yearoutcomesforthepanamericancollaborativeretinastudygroup AT silviolujan intravitrealbevacizumabmonotherapyinmyopicchoroidalneovascularisation5yearoutcomesforthepanamericancollaborativeretinastudygroup AT sergiorojas intravitrealbevacizumabmonotherapyinmyopicchoroidalneovascularisation5yearoutcomesforthepanamericancollaborativeretinastudygroup AT martinserrano intravitrealbevacizumabmonotherapyinmyopicchoroidalneovascularisation5yearoutcomesforthepanamericancollaborativeretinastudygroup AT mariahberrocal intravitrealbevacizumabmonotherapyinmyopicchoroidalneovascularisation5yearoutcomesforthepanamericancollaborativeretinastudygroup AT jfernandoarevalo intravitrealbevacizumabmonotherapyinmyopicchoroidalneovascularisation5yearoutcomesforthepanamericancollaborativeretinastudygroup |